COVID-19: long-term health impacts

Cover Page

Cite item

Full Text

Abstract

Several studies have recently been conducted showing persistent COVID-19 symptoms in patients recovering after the acute phase of the disease. Energy imbalance plays a leading role in the pathogenesis of post-COVID syndrome. The choice of a metabolic cytoprotection drug with anti-asthenic activity will be decisive for the further tactics of managing the patient not only in the hospital, but also during the entire further period of recovery after the infection.

About the authors

Karine R. Badalyan

Pirogov Russian National Research Medical University

Email: kalliroya@mail.ru
ORCID iD: 0000-0002-2820-6399

Cand. Sci. (Med.)

Russian Federation, Moscow

Ella Iu. Solovyeva

Pirogov Russian National Research Medical University

Author for correspondence.
Email: ellasolovieva@yandex.ru
ORCID iD: 0000-0003-1256-2695

D. Sci. (Med.), Prof.

Russian Federation, Moscow

References

  1. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141-54. doi: 10.1038/s41579-020-00459-7
  2. Ellul MA, Benjamin L, Singh B, et al. Neurological associations of COVID-19. Lancet Neurol. 2020;19:767-83. DOI:10.1016/ S1474-4422(20)30221-0
  3. Fernandez-de-las-Penas C, Gomez-Mayordomo V, Cuadrado ML, et al. The presence of headache at onset in SARS-CoV-2 infection is associated with long-term post-COVID headache and fatigue: A case-control study. Cephalalgia. 2021;41(13):1332-41.
  4. Machado C, Gutierrez JV. Brainstem Dysfunction in SARS-COV2 Infection Can Be a Potential Cause of Respiratory Distress. Preprints. 2020:2020040330. doi: 10.20944/preprints202004.0330.v1
  5. Haidar MA, Shakkour Z, Reslan MA, et al. SARS-CoV-2 involvement in central nervous system tissue damage. Neural Regen Res. 2022;17(6):1228-1239.
  6. COVID Symptom Study. How long does COVID-19 last? Kings College, London, 2020. Available at: https://covid19.joinzoe.com/post/covid-long-term?fbclid=IwAR1RxIcmmdL-EFjh_aI-. Accessed: 15.03.2021.
  7. Greenhalgh T, Knight M, A'Court C, et al. Management of post-acute COVID-19 in primary care. BMJ. 2020;370:m3026.
  8. COVID-19 rapid guideline: managing the long-term effects of COVID-19. London: National Institute for Health and Care Excellence (NICE), 2021.
  9. Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324:782-93.
  10. Tenforde M, Kim S, Lindsell C, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network – United States. MMWR. 2020;69:993-8.
  11. Covid-19-long-term-health-effects. Available at https://www.gov.uk/government/publications/covid-19-long-term-health-effects/covid-19-long-term-health-effects. Accessed: 15.03.2021.
  12. Moreno-Pérez O, Merino E, Leon-Ramirez JM, et al. COVID19-ALC research Post-acute COVID-19 Syndrome. Incidence and risk factors: a Mediterranean cohort study. J Infect. 2021;82(3):378-83. doi: 10.1016/j.jinf.2021.01.004
  13. Le Bon SD, Pisarski N, Verbeke J, et al. Psychophysical evaluation of chemosensory functions 5 weeks after olfactory loss due to COVID-19: a prospective cohort study on 72 patients. Eur Arch Otorhinolaryngol. 2020;278:101-8.
  14. Garg P, Arora U, Kumar A, et al. The “post-COVID” syndrome: How deep is the damage? J Med Virol. 2021;93:673-4.
  15. Marcora SM, Staiano W, Manning V. Mental fatigue impairs physical performance in humans. J Appl Physiol (1985). 2009;106(3):857-64. doi: 10.1152/japplphysiol.91324.2008
  16. Katz BZ, Collin SM, Murphy G, et al. The international collaborative on fatigue following infection (COFFI). Fatigue. 2018;6(2):106-21.
  17. Oliviero A, de Castro F, Coperchini F, et al. COVID-19 pulmonary and olfactory dysfunctions: is the chemokine CXCL10 the common denominator? Neuroscientist. 2020;27(3):214-21. doi: 10.1177/1073858420939033
  18. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021. doi: 10.1016/S0140-6736(20)32656-8
  19. Logue JK, Franko NM, McCulloch DJ, et al. Sequelae in adults at 6 months after COVID-19 infection. JAMA Netw Open. 2021;4:e210830.
  20. Graham EL, Clark JR, Orban ZS, et al. Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 “long haulers”. Ann Clin Transl Neurol. 2021;8:1073-85.
  21. Islam MA, Alam SS, Kundu S, et al. Prevalence of headache in patients with Coronavirus Disease 2019 (COVID-19): A systematic review and meta-analysis of 14,275 patients. Front Neurol. 2020;11:562634.
  22. Carfi A, Bernabei R, Landi F. Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603-5.
  23. Arnold DT, Hamilton FW, Milne A, et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax. 2020;76:399-401.
  24. Lombardo MDM, Foppiani A, Peretti GM, et al. Long-Term Coronavirus Disease 2019 Complications in Inpatients and Outpatients: A One-Year Follow-up Cohort Study. Open Forum Infect Dis. 2021;8(8):ofab384. doi: 10.1093/ofid/ofab384
  25. Ortelli P, Ferrazzoli D, Sebastianelli L, et al. Neuropsychological and neurophysiological correlates of fatigue in post-acute patients with neurological manifestations of COVID-19: Insights into a challenging symptom. J Neurol Sci. 2021;420:117271. doi: 10.1016/j.jns.2020.117271
  26. Crunfli F, Carregari VC, Veras FP, et al. SARS-CoV-2 infects brain astrocytes of COVID-19 patients and impairs neuronal viability. medRxiv preprint. 2021. doi: 10.1101/2020.10.09.20207464
  27. Meinhardt J, Radke J, Dittmayer C, et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci. 2021;24(2):168-75. doi: 10.1038/s41593-020-00758-5
  28. Duan K, Premi E, Pilotto A, et al. Alterations of frontal-temporal gray matter volume associate with clinical measures of older adults with COVID-19. Calhoun. Neurobiol Stress. 2021;14:100326. doi: 10.1016/j.ynstr.2021.100326
  29. Karimi-Galougahi M, Yousefi-Koma A, Bakhshayeshkaram M, et al. 18FDG PET/CT Scan Reveals Hypoactive Orbitofrontal Cortex in Anosmia of COVID-19. Acad Radiol. 2020;27(7):1042-3. doi: 10.1016/j.acra.2020.04.030
  30. Bellan M, Soddu D, Balbo PE, et al. Respiratory and Psychophysical Sequelae Among Patients With COVID-19 Four Months After Hospital Discharge. JAMA Netw Open. 2021;4(1):e2036142. doi: 10.1001/jamanetworkopen.2020.36142
  31. Chang D, Park D. Park Incidence of Post-Traumatic Stress Disorder After Coronavirus Disease. Healthcare (Basel). 2020;8(4):373. doi: 10.3390/health care8040373
  32. Taquet M, Geddes JR, Husain M, et al. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8:416-27.
  33. Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry. 2021;8:130-40.
  34. Watson CJ, Thomas RH, Solomon T, et al. COVID-19 and psychosis risk: real or delusional concern? Neurosci Lett. 2021;741:135491.
  35. Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020;277:2251-61.
  36. Addison AB, Wong B, Ahmed T, et al. Clinical Olfactory Working Group Consensus Statement on the Treatment of Post Infectious Olfactory Dysfunction. J Allergy Clin Immunol. 2021;147(5):1704-19. doi: 10.1016/j.jaci.2020.12.641
  37. Emamikhah M, Babadi M, Mehrabani M, et al. Opsoclonus-myoclonus syndrome, a post-infectious neurologic complication of COVID-19: case series and review of literature. J Neurovirol. 2021;27(1):26-34. doi: 10.1007/s13365-020-00941-1
  38. Scoppettuolo P, Borrelli S, Naeije G. Neurological involvement in SARS-CoV-2 infection: A clinical systematic review. Brain Behav Immun Health. 2020;5:100094. doi: 10.1016/j.bbih.2020.100094
  39. Fotuhi M, Mian A, Meysami S, Raji CA. Neurobiology of COVID-19. J Alzheimers Dis. 2020;76:3-19.
  40. Kakumoto T, Kobayashi S, Yuuki H, et al. Cranial Nerve Involvement and Dysautonomia in Post-COVID-19 Guillain-Barré Syndrome. Intern Med. 2021;60:3477-80. doi: 10.2169/internalmedicine.7355-21
  41. Trujillo Gittermann LM, Valenzuela Feris SN, von Oetinger Giacoman A. Relation between COVID-19 and Guillain-Barré syndrome in adults. Systematic review. Neurologia (Engl Ed). 2020;35(9):646-54. doi: 10.1016/j.nrl.2020.07.004
  42. Гимоян Л.Г., Силванян Г.Г. Применение милдроната в лечении когнитивных нарушений при сосудистой деменции. РМЖ. 2017;21:1518-24 [Gimoian LG, Silvanian GG. Primenenie mildronata v lechenii kognitivnykh narushenii pri sosudistoi dementsii. RMZh. 2017;21:1518-24 (in Russian)].
  43. Недогода С.В. Мельдоний как наднозологический препарат. Consilium Medicum. 2020;22(5):57-61 [Nedogoda SV. Meldonium as a supernosological drug. Consilium Medicum. 2020;22(5):57-61 (in Russian)]. doi: 10.26442/20751753.2020.5.200208
  44. Танашян М.М., Максимова М.Ю., Шабалина А.А., и др. Хронические формы нарушений мозгового кровообращения и нейропротекция: клиническая эффективность применения мельдония (Милдронат). Журнал неврологии и психиатрии им. С.С. Корсакова. 2020;120(10):14-21 [Tanashian MM, Maksimova MIu, Shabalina AA, et al. Khronicheskie formy narushenii mozgovogo krovoobrashcheniia i neiroprotektsiia: klinicheskaia effektivnost' primeneniia mel'doniia (Mildronat). Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2020;120(10):14-21 (in Russian)].
  45. Верткин А.Л., Шишкова В.Н., Сычева А.С., и др. Возможности метаболической поддержки при коронавирусной инфекции. Терапия. 2020;7(41):68-76 [Vertkin AL, Shishkova VN, Sycheva AS, et al. Vozmozhnosti metabolicheskoi podderzhki pri koronavirusnoi infektsii. Terapiia. 2020;7(41):68-76 (in Russian)]. doi: 10.18565/therapy.2020.7.146-155
  46. Sellers SA, Hagan RS, Hayden FG, Fischer WA. The hidden burden of influenza: a review of the extra-pulmonary complications of influenza infection. Influenza Other Respir Viruses. 2017;11(5):372-93. doi: 10.1111/irv.12470

Copyright (c) 2021 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies